Clinical Trial

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate how a medicine, LY3841136, works in participants with different levels of liver damage and in participants with healthy liver. The researchers want to see how the medicine is absorbed and used by the body, and if it causes any side effects, in participants with mild, moderate, or severe liver damage, as well as in participants with normal liver function. For each participant, the study will last about 14 weeks, which will include a stay at the clinical research unit for 5 nights.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-02-04; most recent amendment 2026-06-03.
Status change: Not Yet Recruiting → Recruiting 2026-03-19
Trial Details
NCT Number NCT07401862
Lead Sponsor Eli Lilly and Company
Conditions Hepatic Insufficiency
Enrollment 36 participants
Start Date 2026-02-10
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-04